Milestone Pharmaceuticals Inc. (MIST): Capital Expenditures
$302.0K
Year ended 2025-12-31
$356.0K
Trailing 12 months to 2026-06-30
+3.5%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $302.0K | +815.2% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $33.0K | -70.5% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $112.0K | -58.8% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $272.0K | n/a | 2024-03-21, From 2022-01-01 |
| No annual figure between 2019-12-31 and 2022-12-31. | |||
| 2019-12-31 | $413.0K | n/m | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | $5.0K | n/a | 2020-10-23, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $302.0K | +815.2% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $4.0K | -97.2% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $29.0K | -95.6% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $95.0K | -12.8% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $581.0K | +464.1% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $0 | -100.0% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $38.0K | -85.7% |
Compare MIST, KRRO, RFL, PMVP side by side · Screen every company in Pharmaceutical Preparations ↗